Schafer EJ et al (2025) Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol 87(3):302–313. https://doi.org/10.1016/J.EURURO.2024.11.013

Article  PubMed  PubMed Central  Google Scholar 

Wolff RF et al (2015) A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer 51(16):2345–2367. https://doi.org/10.1016/j.ejca.2015.07.019

Article  PubMed  Google Scholar 

Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060. https://doi.org/10.1016/S1470-2045(16)30102-4

Article  PubMed  PubMed Central  Google Scholar 

King CR, Brooks JD, Gill H, Presti JC (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Adv Radiat Oncol 82(2):877–882. https://doi.org/10.1016/j.ijrobp.2010.11.054

Article  PubMed  Google Scholar 

Kishan AU et al (2019) Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. https://doi.org/10.1001/JAMANETWORKOPEN.2018.8006

Article  PubMed  PubMed Central  Google Scholar 

Widmark A et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet 394(10196):385–395. https://doi.org/10.1016/S0140-6736(19)31131-6

Article  Google Scholar 

Draulans C et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Clin Transl Radiat Oncol 147:92–98. https://doi.org/10.1016/j.radonc.2020.03.015

Article  PubMed  Google Scholar 

van As N et al (2023) 5‑Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer. Adv Radiat Oncol 117(4):e2–e3. https://doi.org/10.1016/j.ijrobp.2023.08.027

Article  Google Scholar 

Spratt DE et al (2025) NCCN Guidelines Version 1.2026 Prostate Cancer NCCN Guidelines Panel Disclosures. www.nccn.org/home/. Accessed 3.9.2025

Kishan AU et al (2023) Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol 9(3):365–373. https://doi.org/10.1001/jamaoncol.2022.6558

Article  PubMed  PubMed Central  Google Scholar 

Neylon J et al (2024) Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys 118(5):1181–1191. https://doi.org/10.1016/J.IJROBP.2023.12.035

Article  PubMed  Google Scholar 

Ugurluer G et al (2020) Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity. Br J Radiol 94(1117):20200696. https://doi.org/10.1259/BJR.20200696

Article  PubMed  PubMed Central  Google Scholar 

Akyol F, Ozyigit G, Selek U, Karabulut E (2005) PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol Oncol 48(1):40–45. https://doi.org/10.1016/j.eururo.2005.04.007

Article  CAS  PubMed  Google Scholar 

“Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer - PubMed.” Accessed: Jul. 16, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/10875459/

Gelbart Pridan O et al (2023) Outcome of the first 200 patients with prostate cancer treated with MRI-Linac at Assuta MC. Front Oncol 13:1151256. https://doi.org/10.3389/FONC.2023.1151256/BIBTEX

Article  PubMed  PubMed Central  Google Scholar 

Catton CN et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35(17):1884–1890. https://doi.org/10.1200/JCO.2016.71.7397

Article  CAS  PubMed  Google Scholar 

Incrocci L et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17(8):1061–1069. https://doi.org/10.1016/S1470-2045(16)30070-5

Article  PubMed  Google Scholar 

Schaulin MS, Delouya G, Zwahlen D, Taussky D (2024) Tracing the Evolution of Prostate Brachytherapy in the 20th Century. Oncology 102(3):283–290. https://doi.org/10.1159/000534017

Article  PubMed  Google Scholar 

Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Adv Radiat Oncol 67(4):1099–1105. https://doi.org/10.1016/j.ijrobp.2006.10.050

Article  PubMed  Google Scholar 

Jackson WC et al (2019) Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Adv Radiat Oncol 104(4):778–789. https://doi.org/10.1016/j.ijrobp.2019.03.051

Article  PubMed  PubMed Central  Google Scholar 

van As N et al (2024) Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE‑A Randomised Trial. Eur Urol Oncol 86(6):566–576. https://doi.org/10.1016/j.eururo.2024.08.030

Article  PubMed  Google Scholar 

“Study Details | NCT01794403 | Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer | ClinicalTrials.gov.” Accessed: Nov. 23, 2025. [Online]. Available: https://www.clinicaltrials.gov/study/NCT01794403

Tree AC et al (2025) Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 26(7):936–947. https://doi.org/10.1016/S1470-2045(25)00205-0

Article  PubMed  PubMed Central  Google Scholar 

Zamboglou C et al (2022) PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2‑Armed Phase 2 Trial (ARO2020-01). Adv Radiat Oncol 113(5):1025–1035. https://doi.org/10.1016/j.ijrobp.2022.04.020

Article  PubMed  Google Scholar 

Spohn SKB et al (2025) Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01). Clin Transl Radiat Oncol. https://doi.org/10.1016/j.radonc.2025.110883

Article  PubMed  Google Scholar 

De Cock L et al (2023) From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Clin Transl Radiat Oncol. https://doi.org/10.1016/j.radonc.2023.109713

Article  PubMed  Google Scholar 

Ma TM et al (2022) Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. Clin Transl Radiat Oncol 167:203–210. https://doi.org/10.1016/j.radonc.2021.12.037

Article  PubMed  Google Scholar 

Vanhanen A, Reinikainen P, Kapanen M (2022) Radiation-induced prostate swelling during SBRT of the prostate. Acta Oncol (Madr) 61(6):698–704. https://doi.org/10.1080/0284186X.2022.2062682

Article  CAS  Google Scholar 

Ray ME et al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Adv Radiat Oncol 64(4):1140–1150. https://doi.org/10.1016/j.ijrobp.2005.07.006

Article  PubMed  Google Scholar 

Zelefsky MJ et al (2009) Postradiotherapy 2‑Year Prostate-Specific Antigen Nadir as a Predictor of Long-Term Prostate Cancer Mortality. Int J Radiat Oncol Biol Phys 75(5):1350–1356. https://doi.org/10.1016/J.IJROBP.2008.12.067

Article  PubMed  Google Scholar 

ME R et al (2006) Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. https://doi.org/10.1016/J.UROLOGY.2006.08.1056

Article  Google Scholar 

Rosser CJ et al (2002) The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. Journal of Urology 168(5):2001–2005. https://doi.org/10.1016/S0022-5347(05)64282-6

Article  CAS